Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several key label-grounded claims are marked absent from the provided label, including episodic vs chronic migraine indication wording, plus inaccurate/overbroad safety counseling and an injection-site swelling claim marked absent. Overall alignment is poor relative to the supplied prescribing information.
Category Scores
Accurate Statements
Aimovig is a prescription migraine prevention medicine.
Indications and Usage: “AIMOVIG is indicated for the preventive treatment of migraine in adults.” (1 INDICATIONS AND USAGE)
Aimovig is erenumab.
Contraindications section references erenumab-aooe; Mechanism of Action section identifies CGRP receptor antagonism by erenumab-aooe. (4 CONTRAINDICATIONS; 12 CLINICAL PHARMACOLOGY (12.1))
Aimovig is given as a subcutaneous injection using an auto-injector.
Administration instructions: intended for self-administration using the single-dose prefilled autoinjector (subcutaneous use only). (2 DOSAGE AND ADMINISTRATION (2.2))
The Aimovig injector is designed for self-administration under the skin (subcutaneous).
Self-administration and subcutaneous instructions for the autoinjector. (2 (2.2))
Commonly reported side effects with erenumab injections include injection-site reactions.
Most common adverse reactions include injection site reactions. (6.1 Clinical Trials Experience)
Injection-site reactions include pain.
Most frequent injection site reactions include injection site pain. (6.1 Clinical Trials Experience)
Commonly reported side effects with erenumab injections include constipation.
Constipation with serious complications warning; and most common adverse reactions include constipation. (5.2; 6.1)
Aimovig works through the CGRP pathway.
Binds to CGRP receptor and antagonizes CGRP receptor function. (12.1 Mechanism of Action)
Unsupported Statements
Injection-site reactions include swelling.
Marked absent from the provided label evaluation; the supplied excerpts only explicitly list injection site pain/erythema/pruritus as the most frequent injection site reactions, and do not support swelling as a listed injection-site reaction claim. (6.1)
Contradictions
Important Omissions
Episodic vs chronic migraine indication wording is incorrectly stated in ways assessed as absent from the label in the provided evaluation (two indication claims).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Misalignment in indication description and incomplete/incorrect safety counseling (e.g., specific injection-site reaction characterization and prompt guidance phrasing) can affect appropriate use and recognition of labeled serious issues.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Key indication and safety-related claims do not reliably align with the provided FDA label excerpts (episodic/chronic wording errors; injection-site swelling claim unsupported; safety counseling specificity issues).
Suggested Improvement
Rephrase indication statements strictly to match the label’s single indication wording for prevention of migraine in adults, remove unsupported injection-site reaction details (e.g., swelling), and ensure hypersensitivity/constipation counseling matches the labeled guidance (serious/severe hypersensitivity: discontinue and initiate appropriate therapy; monitor for severe constipation and manage as clinically appropriate).